Orthofix Medical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
37.6%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$843.3Mnext fiscal year
FY EPS (est.)
$0.27next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 3 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Global Net Sales Quarterly196.7MTarget: 850000000 - 860000000
Non-GAAP Adjusted EBITDA Quarterly9.7MTarget: 95000000 - 98000000
R&D Investment as % of Sales AnnuallyTarget: 7% - 8%
Watch Items
- Medicare Reimbursement Rates for Non-Invasive Bone Growth StimulatorsTrigger: Further cuts beyond the ~10% reduction implemented by CMS on May 18, 2026Action: Monitor CMS implementation of the July 1, 2026 revised guidance, track claim volumes and payer behavior, and evaluate the long-term impact of future CMS actions on the bone growth stimulation business.
- Free Cash Flow GenerationTrigger: Prolonged negative free cash flow throughout fiscal year 2026Action: Assess liquidity preservation measures, review capital expenditure, and optimize working capital to mitigate cash burn.
- U.S. Spine and Limb Reconstruction Commercial Channel TransitionsTrigger: Slowing distributor productivity or failure of top 30 partners to maintain high-growth trajectoryAction: Re-examine distributor incentives, enhance field execution support, and accelerate product pull-through.
Research as of 19 Jun 2026